Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
